Company / Working Capital
Akebia Therapeutics, Inc. Working Capital History
FY2014-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Working Capital
$90.0M
FY2025
5-year range
$15.5M / $90.0M
FY2021-FY2025
Trend
+173.5%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Working Capital has fluctuated over the past 10 years, ranging from $16M in FY2021 to $203M in FY2018.
Based on SEC 10-K filings.
$90M in FY2025 with a 10-year CAGR of -3.5%.
Improved from $18M to $90M over the past 2 years.
Working Capital over time
Growth rates
- 3-Year CAGR
- +17.4%
- 5-Year CAGR
- -13.4%
- 10-Year CAGR
- -3.5%
Key checks
Key Insights
- 5-year CAGR of -13.4%, indicating a declining trend.
- In FY2025, working capital increased 173.5% year-over-year.
- Peak working capital was recorded in FY2018.
- Lowest working capital in the period was in FY2021.
Company context
Key Data Points
- Altman Z-Score -2.76 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Working CapitalValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $90.0M | +173.5% |
| FY2024 | $32.9M | +80.1% |
| FY2023 | $18.3M | -67.2% |
| FY2022 | $55.6M | +258.6% |
| FY2021 | $15.5M | -91.6% |
| FY2020 | $184.3M | +81.7% |
| FY2019 | $101.4M | -49.9% |
| FY2018 | $202.6M | +56.9% |
| FY2015 | $129.1M | +24.7% |
| FY2014 | $103.6M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026